DEF: Gaxos.ai Inc. Sets 2025 Annual Meeting Agenda, Proposes Significant Equity Plan Expansion

Gaxos.ai Inc. has announced its 2025 Annual Meeting of Shareholders, where key proposals include the election of directors, auditor ratification, and a substantial increase in shares reserved for its equity incentive plan.

Summary

• Gaxos.ai Inc. will hold its 2025 Annual Meeting of Shareholders on Tuesday, August 12, 2025, at 9:00 a.m. Eastern Time, at its office located at 101 Eisenhower Parkway, Suite 300, Roseland, NJ 07068.
• Shareholders will vote on three primary proposals: the election of four directors (Vadim Mats, Adam Holzer, Scott A. Grayson, and Roman Feldman), the ratification of Salberg & Company, P.A. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and the approval of an amendment to the 2022 Omnibus Equity Incentive Plan.
• The proposed Plan Amendment seeks to increase the number of shares of common stock reserved for issuance under the 2022 Plan from 553,637 to 803,637 shares, which represents approximately 11.28% of the company's 7,123,453 outstanding common shares as of the June 20, 2025 Record Date.
• The Board of Directors unanimously recommends a 'FOR' vote on all three proposals.
• As of December 31, 2024, 64,084 options were outstanding under equity compensation plans with a weighted average exercise price of $31.35, and 239,553 securities remained available for future issuance.
• CEO Vadim Mats's total compensation for 2024 was $550,000, comprising a $400,000 salary and a $150,000 bonus, a decrease from $861,869 in 2023.
• CFO Steven Shorr's total compensation for 2024 was $60,000, down from $118,407 in 2023.
• Non-employee directors Adam Holzer, Alex Kisin (who resigned March 3, 2025), and Scott Grayson each received $24,000 in cash fees and $11,293 in option awards in 2024.
• Audit fees paid to Salberg & Company, P.A. for 2024 totaled $78,000, including $67,000 for audit services and $11,000 for audit-related consulting services.

Sentiment

Score: 6

Explanation: The document is a routine proxy statement outlining standard corporate governance procedures and a common request for equity plan expansion. There are no significant positive operational announcements or major negative disclosures. The proactive approach to talent retention through equity and adherence to governance practices contribute to a neutral-to-slightly-positive sentiment.

Positives

• The Board of Directors unanimously recommends approval of all proposals, indicating strong internal alignment and confidence in the proposed actions.
• The company maintains a majority independent board, with three out of four nominated directors considered independent, reinforcing objective oversight.
• Established corporate governance practices are in place, including a Code of Business Conduct and Ethics, and charters for the audit, compensation, and nominating/corporate governance committees.
• The Audit Committee is composed entirely of independent directors, with Scott A. Grayson identified as a financial expert, enhancing financial oversight capabilities.
• All current directors attended at least 75% of the aggregate Board and committee meetings during the 2024 fiscal year, demonstrating active engagement.
• The formation of a Medical Advisory Board in February 2024, with members listed as of March 15, 2025, suggests a strategic focus or expansion into areas requiring specialized expertise.
• An Insider Trading Policy has been adopted, prohibiting short sales, hedging, margin purchases, and pledging of company securities by insiders, promoting ethical conduct and compliance.

Negatives

• The Compensation Committee and Nominating and Corporate Governance Committee did not hold any meetings during the 2024 fiscal year, which could suggest less active oversight in these critical areas.
• The proposed increase in the 2022 Equity Incentive Plan shares to 803,637 represents approximately 11.28% dilution of outstanding common stock, which may be a concern for existing shareholders.
• The closing trading price of the common stock as of the Record Date was $1.38, which is significantly lower than the $49.80 exercise price of options granted to executives in February 2023.
• Total compensation for CEO Vadim Mats decreased from $861,869 in 2023 to $550,000 in 2024, and for CFO Steven Shorr from $118,407 in 2023 to $60,000 in 2024, primarily due to the absence of new option awards in 2024 compared to 2023.

Risks

• Failure to approve the Plan Amendment could result in insufficient shares available for continued equity awards, potentially hindering the company's ability to attract, motivate, and retain highly qualified talent.
• The approval of the Plan Amendment will lead to an approximate 11.28% dilution of the company's outstanding common stock, which could impact existing shareholder value.
• There is a risk of broker non-votes on non-routine proposals, such as the election of directors and the Plan Amendment, if shareholders holding shares in street name do not provide specific voting instructions, potentially affecting the voting outcomes.
• The company's decision to combine the roles of Chairman and Chief Executive Officer, citing company size, could be perceived by some governance experts as a potential risk to independent board oversight.

Future Outlook

The company anticipates that the additional shares requested under the Plan Amendment, combined with existing available shares, will be sufficient for equity awards for a period of two years. This is expected to enable the continued attraction, retention, and motivation of key talent, which is considered essential for achieving business objectives and creating greater value for shareholders.

Management Comments

• "Our Board unanimously recommends that you vote: FOR the election of our Boards director nominees (Proposal 1); FOR the ratification of the appointment of Salberg as our independent registered public accounting firm for the fiscal year ending December 31, 2025 (Proposal 2); and FOR the approval of the Plan Amendment (Proposal 3)."
• "We believe that Mr. Mats is best situated to serve as Chairman because he is the director most familiar with the Companys business and industry and is also the person most capable of effectively identifying strategic priorities and leading the discussion and execution of corporate strategy."
• "We recognize the dilutive impact of our equity compensation program on our shareholders and continuously strive to balance this concern with the competition for talent in the competitive business environment and talent market, as well as the current market conditions, in which we operate."
• "As exhibited by our responsible use of equity over the past several years and good corporate governance practices associated with equity and executive compensation practices in general, we believe the stock reserved under the 2022 Plan, as amended pursuant to the Plan Amendment, will provide us with the platform needed for our continued growth, while managing program costs and share utilization levels within acceptable industry standards."

Industry Context

This document is a standard proxy statement primarily focused on corporate governance, executive compensation, and an equity plan amendment. It does not provide specific details on broader industry trends or competitive positioning within the artificial intelligence sector, beyond general statements about the competitive talent market. The company's name, Gaxos.ai Inc., suggests involvement in artificial intelligence, but the filing itself does not elaborate on specific industry dynamics or how the company's operations relate to them.

Comparison to Industry Standards

• The document states that the proposed equity plan, if amended, will allow the company to manage program costs and share utilization levels within "acceptable industry standards," but it does not provide specific comparable companies, projects, or global benchmarks for a detailed assessment.
• The dilution of approximately 11.28% from the proposed equity plan expansion is a factor to consider, but without specific peer group data or industry-specific benchmarks for similar-stage companies, a direct comparison to broader industry standards is not possible based solely on this document.

Management Changes

Corporate Governance

Legal Proceedings

• No involvement of directors or officers in any material legal proceedings (bankruptcy, insolvency, criminal, or other Item 401(f) matters) in the past ten years was mentioned.

Related Party Transactions

• No material related party transactions exceeding the lesser of $120,000 or 1% of average total assets were disclosed for the fiscal years ended December 31, 2024, and 2023, other than executive employment arrangements detailed under Executive Compensation.
• The company has adopted a related person transaction policy that outlines procedures for the identification, review, consideration, and approval or ratification of related person transactions exceeding specified thresholds.

Stakeholder Impact

• Shareholders will directly impact corporate governance by voting on director elections, auditor ratification, and the proposed equity incentive plan amendment, which could lead to share dilution.
• Employees, officers, directors, and consultants are directly impacted by the 2022 Equity Incentive Plan, as it provides the framework for equity-based compensation designed to attract, motivate, and retain talent.
• Salberg & Company, P.A. is proposed for ratification as the independent registered public accounting firm for fiscal year 2025, ensuring continuity of external audit services.

Next Steps

• Hold the 2025 Annual Meeting of Shareholders on August 12, 2025, where shareholders will vote on the proposed matters.
• File a Current Report on Form 8-K with the SEC within four business days after the Annual Meeting to disclose the final voting results.
• If final voting results are not available in time, file a Form 8-K with preliminary results and a subsequent Form 8-K with final results.
• Shareholders intending to submit a proposal for inclusion in the 2026 Annual Meeting proxy materials must do so by March 2, 2026.
• Shareholders intending to present a proposal at the 2026 Annual Meeting without inclusion in proxy materials must provide notice between April 14, 2026, and May 14, 2026.
• Shareholders intending to solicit proxies for director nominees under universal proxy rules for the 2026 Annual Meeting must submit notice by June 13, 2026.

Key Dates

Recommendation

Keywords

Gaxos.ai Inc., proxy statement, annual meeting, corporate governance, equity incentive plan, stock options, executive compensation, independent auditor, shareholder vote, SEC filing, DEF 14A